ARCTURUS THERAPEUTICS HLDGS's ticker is ARCT and the CUSIP is 03969T109. A total of 140 filers reported holding ARCTURUS THERAPEUTICS HLDGS in Q2 2021. The put-call ratio across all filers is 1.33 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $195,000 | +34.5% | 7,631 | +50.4% | 0.00% | – |
| Q2 2023 | $145,000 | -12.1% | 5,073 | -26.3% | 0.00% | – |
| Q1 2023 | $165,000 | +63.4% | 6,886 | +15.1% | 0.00% | – |
| Q4 2022 | $101,000 | +68.3% | 5,981 | +47.8% | 0.00% | – |
| Q3 2022 | $60,000 | -10.4% | 4,047 | -4.1% | 0.00% | – |
| Q2 2022 | $67,000 | -58.9% | 4,220 | -30.1% | 0.00% | – |
| Q1 2022 | $163,000 | -55.9% | 6,036 | -39.6% | 0.00% | – |
| Q4 2021 | $370,000 | +3.9% | 9,989 | +34.2% | 0.00% | – |
| Q3 2021 | $356,000 | +423.5% | 7,442 | +273.0% | 0.00% | – |
| Q2 2021 | $68,000 | -16.0% | 1,995 | +1.7% | 0.00% | – |
| Q1 2021 | $81,000 | -39.1% | 1,961 | -36.2% | 0.00% | – |
| Q4 2020 | $133,000 | -75.8% | 3,076 | -76.0% | 0.00% | – |
| Q3 2020 | $550,000 | +64.7% | 12,831 | +80.0% | 0.00% | – |
| Q2 2020 | $334,000 | +2285.7% | 7,130 | +613.0% | 0.00% | – |
| Q1 2020 | $14,000 | +1300.0% | 1,000 | +719.7% | 0.00% | – |
| Q3 2019 | $1,000 | – | 122 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DFPG INVESTMENTS, LLC | 456,390 | $5,541,000 | 3.62% |
| DAFNA Capital Management LLC | 173,914 | $1,890,000 | 0.65% |
| One68 Global Capital, LLC | 19,861 | $216,000 | 0.47% |
| Diametric Capital, LP | 51,982 | $565,000 | 0.41% |
| ARK Investment Management | 1,383,756 | $15,041,000 | 0.38% |
| EAM Investors, LLC | 52,833 | $574,000 | 0.13% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 31,404 | $341,000 | 0.05% |
| Nikko Asset Management Americas, Inc. | 280,548 | $3,050,000 | 0.05% |
| MGO ONE SEVEN LLC | 14,900 | $161,000 | 0.04% |
| Qube Research & Technologies Ltd | 67,702 | $736,000 | 0.02% |